Yunnan Hongxiang Yixintang
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, engages in the pharmaceutical retail chain and pharmaceutical distribution business. The company is involved in the wholesale, retail, leasing, and operation of medical devices; sale of food, disinfectants, disinfection equipment, sanitary products and disposable medical products, household appliances, adult toys, agricultura… Read more
Yunnan Hongxiang Yixintang (002727) - Net Assets
Latest net assets as of September 2025: CN¥7.47 Billion CNY
Based on the latest financial reports, Yunnan Hongxiang Yixintang (002727) has net assets worth CN¥7.47 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥15.84 Billion) and total liabilities (CN¥8.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.47 Billion |
| % of Total Assets | 47.15% |
| Annual Growth Rate | 25.2% |
| 5-Year Change | 32.4% |
| 10-Year Change | 236.71% |
| Growth Volatility | 28.55 |
Yunnan Hongxiang Yixintang - Net Assets Trend (2009–2024)
This chart illustrates how Yunnan Hongxiang Yixintang's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yunnan Hongxiang Yixintang (2009–2024)
The table below shows the annual net assets of Yunnan Hongxiang Yixintang from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.65 Billion | -2.84% |
| 2023-12-31 | CN¥7.88 Billion | +4.64% |
| 2022-12-31 | CN¥7.53 Billion | +12.81% |
| 2021-12-31 | CN¥6.67 Billion | +15.43% |
| 2020-12-31 | CN¥5.78 Billion | +25.77% |
| 2019-12-31 | CN¥4.60 Billion | +13.50% |
| 2018-12-31 | CN¥4.05 Billion | +9.63% |
| 2017-12-31 | CN¥3.69 Billion | +47.87% |
| 2016-12-31 | CN¥2.50 Billion | +9.91% |
| 2015-12-31 | CN¥2.27 Billion | +9.14% |
| 2014-12-31 | CN¥2.08 Billion | +98.33% |
| 2013-12-31 | CN¥1.05 Billion | +29.52% |
| 2012-12-31 | CN¥810.77 Million | +28.94% |
| 2011-12-31 | CN¥628.80 Million | +26.41% |
| 2010-12-31 | CN¥497.43 Million | +89.30% |
| 2009-12-31 | CN¥262.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yunnan Hongxiang Yixintang's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9070.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.52 Billion | 60.37% |
| Common Stock | CN¥585.60 Million | 7.82% |
| Other Comprehensive Income | CN¥366.77 Million | 4.90% |
| Other Components | CN¥2.02 Billion | 26.92% |
| Total Equity | CN¥7.49 Billion | 100.00% |
Yunnan Hongxiang Yixintang Competitors by Market Cap
The table below lists competitors of Yunnan Hongxiang Yixintang ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Draper Esprit plc
PINK:GRWXF
|
$545.34 Million |
|
Truking Technology Ltd
SHE:300358
|
$545.42 Million |
|
Zhejiang EV-Tech Co.,Ltd.
SHE:301607
|
$545.53 Million |
|
San Bian Science & Technology Co Ltd
SHE:002112
|
$545.59 Million |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
$545.18 Million |
|
MA Financial Group Ltd
AU:MAF
|
$545.18 Million |
|
5R02
F:5R02
|
$545.09 Million |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
$544.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yunnan Hongxiang Yixintang's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,745,981,105 to 7,491,014,022, a change of -254,967,083 (-3.3%).
- Net income of 114,138,361 contributed positively to equity growth.
- Dividend payments of 260,542,740 reduced retained earnings.
- Share repurchases of 134,723,799 reduced equity.
- Other comprehensive income decreased equity by 11,033,242.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥114.14 Million | +1.52% |
| Dividends Paid | CN¥260.54 Million | -3.48% |
| Share Repurchases | CN¥134.72 Million | -1.8% |
| Other Comprehensive Income | CN¥-11.03 Million | -0.15% |
| Other Changes | CN¥37.19 Million | +0.5% |
| Total Change | CN¥- | -3.29% |
Book Value vs Market Value Analysis
This analysis compares Yunnan Hongxiang Yixintang's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.84x to 1.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.73 | CN¥13.11 | x |
| 2010-12-31 | CN¥1.32 | CN¥13.11 | x |
| 2011-12-31 | CN¥1.60 | CN¥13.11 | x |
| 2012-12-31 | CN¥2.07 | CN¥13.11 | x |
| 2013-12-31 | CN¥2.68 | CN¥13.11 | x |
| 2014-12-31 | CN¥4.57 | CN¥13.11 | x |
| 2015-12-31 | CN¥4.37 | CN¥13.11 | x |
| 2016-12-31 | CN¥4.80 | CN¥13.11 | x |
| 2017-12-31 | CN¥7.10 | CN¥13.11 | x |
| 2018-12-31 | CN¥7.12 | CN¥13.11 | x |
| 2019-12-31 | CN¥8.09 | CN¥13.11 | x |
| 2020-12-31 | CN¥10.06 | CN¥13.11 | x |
| 2021-12-31 | CN¥11.11 | CN¥13.11 | x |
| 2022-12-31 | CN¥12.48 | CN¥13.11 | x |
| 2023-12-31 | CN¥12.98 | CN¥13.11 | x |
| 2024-12-31 | CN¥12.65 | CN¥13.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yunnan Hongxiang Yixintang utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.63%
- • Asset Turnover: 1.07x
- • Equity Multiplier: 2.25x
- Recent ROE (1.52%) is below the historical average (15.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 32.86% | 5.83% | 2.12x | 2.65x | CN¥59.03 Million |
| 2010 | 21.03% | 5.56% | 1.67x | 2.26x | CN¥54.00 Million |
| 2011 | 21.59% | 6.07% | 1.70x | 2.10x | CN¥72.33 Million |
| 2012 | 22.64% | 6.42% | 1.86x | 1.89x | CN¥101.91 Million |
| 2013 | 23.00% | 6.79% | 1.71x | 1.98x | CN¥136.13 Million |
| 2014 | 14.28% | 6.71% | 1.51x | 1.41x | CN¥89.04 Million |
| 2015 | 15.23% | 6.51% | 1.27x | 1.84x | CN¥118.96 Million |
| 2016 | 14.16% | 5.65% | 1.04x | 2.41x | CN¥103.74 Million |
| 2017 | 11.44% | 5.45% | 1.08x | 1.93x | CN¥53.32 Million |
| 2018 | 12.88% | 5.68% | 1.25x | 1.82x | CN¥116.51 Million |
| 2019 | 13.14% | 5.76% | 1.32x | 1.73x | CN¥144.43 Million |
| 2020 | 13.70% | 6.24% | 1.36x | 1.62x | CN¥213.42 Million |
| 2021 | 14.01% | 6.32% | 1.02x | 2.18x | CN¥263.81 Million |
| 2022 | 13.60% | 5.79% | 1.08x | 2.18x | CN¥267.38 Million |
| 2023 | 7.09% | 3.16% | 1.04x | 2.15x | CN¥-225.16 Million |
| 2024 | 1.52% | 0.63% | 1.07x | 2.25x | CN¥-634.96 Million |
Industry Comparison
This section compares Yunnan Hongxiang Yixintang's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,224,173,475
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yunnan Hongxiang Yixintang (002727) | CN¥7.47 Billion | 32.86% | 1.12x | $545.21 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $450.11 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | $856.04 Million | 6.95% | 0.97x | $170.91 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.78 Billion | 1.93% | 1.96x | $174.48 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |